Publicaciones en colaboración con investigadores/as de University Hospital Heidelberg (12)

2023

  1. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935

  2. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

    British Journal of Cancer, Vol. 128, Núm. 1, pp. 137-147

2021

  1. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

    The Lancet Oncology, Vol. 22, Núm. 7, pp. 959-969

2020

  1. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

    British Journal of Cancer, Vol. 123, Núm. 5, pp. 793-802

2018

  1. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

    Mayo Clinic Proceedings, Vol. 93, Núm. 3, pp. 307-320

2017

  1. A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer

    Lung Cancer, Vol. 108, pp. 212-216

  2. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer

    New England Journal of Medicine, Vol. 376, Núm. 25, pp. 2415-2426

  3. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

    Lung Cancer, Vol. 112, pp. 181-187

2015

  1. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

    New England Journal of Medicine, Vol. 373, Núm. 2, pp. 123-135

2014

  1. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials

    Lung Cancer, Vol. 85, Núm. 3, pp. 408-414

  2. Final efficacy and safety Results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study

    Journal of Thoracic Oncology, Vol. 9, Núm. 7, pp. 991-997

  3. Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately after Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer

    Clinical Lung Cancer, Vol. 15, Núm. 6, pp. 418-425